BACKGROUND: Women and minorities continue to account for a higher proportion of AIDS incidence and mortality than their male and white counterparts. This study examined whether race and gender were associated with antiretroviral use among HIV-infected individuals in the southeastern US. METHODS: Multivariate regression analyses were used to identify whether race and gender predicted use of a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) from 1996 to 2000 among individuals receiving HIV primary care. RESULTS: Female gender and nonwhite race were significantly associated with a lower likelihood of being prescribed a PI or NNRTI at baseline. At the follow-up measure three years later, fewer individuals of minority race and female gender were prescribed a PI or NNRTI; however, these differences had declined and were no longer statistically significant. CONCLUSIONS: Efforts are needed to improve prompt access to advances in HIV therapeutics for women and minorities and to address continued disparities in HIV care by race and gender.
BACKGROUND:Women and minorities continue to account for a higher proportion of AIDS incidence and mortality than their male and white counterparts. This study examined whether race and gender were associated with antiretroviral use among HIV-infected individuals in the southeastern US. METHODS: Multivariate regression analyses were used to identify whether race and gender predicted use of a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) from 1996 to 2000 among individuals receiving HIV primary care. RESULTS: Female gender and nonwhite race were significantly associated with a lower likelihood of being prescribed a PI or NNRTI at baseline. At the follow-up measure three years later, fewer individuals of minority race and female gender were prescribed a PI or NNRTI; however, these differences had declined and were no longer statistically significant. CONCLUSIONS: Efforts are needed to improve prompt access to advances in HIV therapeutics for women and minorities and to address continued disparities in HIV care by race and gender.
Authors: Brooke S West; Enrique R Pouget; Barbara Tempalski; Hannah L F Cooper; H Irene Hall; Xiaohong Hu; Samuel R Friedman Journal: Ann Epidemiol Date: 2015-02-07 Impact factor: 3.797
Authors: Benjamin P Linas; Elena Losina; Annette Rockwell; Rochelle P Walensky; Kevin Cranston; Kenneth A Freedberg Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.731
Authors: Christine U Oramasionwu; Carolyn M Brown; Kenneth A Lawson; Laurajo Ryan; Jeff Skinner; Christopher R Frei Journal: South Med J Date: 2011-12 Impact factor: 0.954
Authors: Antoine D Brantley; Samuel Burgess; Jacquelyn Bickham; Deborah Wendell; DeAnn Gruber Journal: Public Health Rep Date: 2018 Nov/Dec Impact factor: 2.792
Authors: Arif Alibhai; Walter Kipp; L Duncan Saunders; Ambikaipakan Senthilselvan; Amy Kaler; Stan Houston; Joseph Konde-Lule; Joa Okech-Ojony; Tom Rubaale Journal: Int J Womens Health Date: 2010-08-09
Authors: Diana C Lemly; Bryan E Shepherd; Todd Hulgan; Peter Rebeiro; Samuel Stinnette; Robert B Blackwell; Sally Bebawy; Asghar Kheshti; Timothy R Sterling; Stephen P Raffanti Journal: J Infect Dis Date: 2009-04-01 Impact factor: 5.226
Authors: Winston E Abara; Lerissa Smith; Shun Zhang; Amanda J Fairchild; Harry J Heiman; George Rust Journal: Am J Public Health Date: 2014-09-11 Impact factor: 9.308
Authors: Audrey L French; Susan H Gawel; Ronald Hershow; Lorie Benning; Nancy A Hessol; Alexandra M Levine; Kathryn Anastos; Michael Augenbraun; Mardge H Cohen Journal: J Acquir Immune Defic Syndr Date: 2009-08-01 Impact factor: 3.731